224 related articles for article (PubMed ID: 35877259)
1. Bortezomib, Lenalidomide and Dexamethasone Combination Induced Complete Remission in Relapsed/Refractory Plasmablastic Lymphoma: Case Report of a Potential Novel Treatment Approach.
Sabry W; Wu Y; Kodad SG
Curr Oncol; 2022 Jul; 29(7):5042-5053. PubMed ID: 35877259
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib- and Lenalidomide-Based Treatment of Refractory Plasmablastic Lymphoma.
Ando K; Imaizumi Y; Kobayashi Y; Niino D; Hourai M; Sato S; Sawayama Y; Hata T; Ohshima K; Miyazaki Y
Oncol Res Treat; 2020; 43(3):112-116. PubMed ID: 31842017
[TBL] [Abstract][Full Text] [Related]
3. Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide.
Cheng L; Song Q; Liu M; Wang Y; Yi H; Qian Y; Xu P; Cheng S; Wang C; Wang L; Zhao W
Front Immunol; 2021; 12():702593. PubMed ID: 34322131
[TBL] [Abstract][Full Text] [Related]
4. Incorporating Bortezomib in the Management of Plasmablastic Lymphoma.
Umeanaeto O; Gamboa J; Diaz J; Hakim MN; Corral J; Philipovskiy A; Gaur S
Anticancer Res; 2019 Sep; 39(9):5003-5007. PubMed ID: 31519607
[TBL] [Abstract][Full Text] [Related]
5. A Case of Plasmablastic Lymphoma Achieving Complete Response and Durable Remission after Lenalidomide-Based Therapy.
Schmit JM; DeLaune J; Norkin M; Grosbach A
Oncol Res Treat; 2017; 40(1-2):46-48. PubMed ID: 28095384
[TBL] [Abstract][Full Text] [Related]
6. [Long-term complete remission of HIV-negative primary testicular plasmablastic lymphoma treated with bortezomib in combination with EPOCH].
Fujishima T; Kawabata Y; Michishita Y; Kitabayashi A; Takahashi N
Rinsho Ketsueki; 2022; 63(10):1386-1391. PubMed ID: 36351644
[TBL] [Abstract][Full Text] [Related]
7. Refractory plasmablastic lymphoma-a review of treatment options beyond standard therapy.
Pretscher D; Kalisch A; Wilhelm M; Birkmann J
Ann Hematol; 2017 Jun; 96(6):967-970. PubMed ID: 28011983
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib in plasmablastic lymphoma: A glimpse of hope for a hard-to-treat disease.
Guerrero-Garcia TA; Mogollon RJ; Castillo JJ
Leuk Res; 2017 Nov; 62():12-16. PubMed ID: 28963907
[TBL] [Abstract][Full Text] [Related]
9. Successful Use of Bortezomib-Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma.
Marrero WD; Cruz-Chacón A; Castillo C; Cabanillas F
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):e275-e277. PubMed ID: 29753690
[No Abstract] [Full Text] [Related]
10. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
Jung KS; Kim K; Kim HJ; Kim SH; Lee JO; Kim JS; Lee JJ; Eom HS; Min CK; Shin HJ
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e97-e104. PubMed ID: 31831372
[TBL] [Abstract][Full Text] [Related]
11. [HIV-negative plasmablastic lymphoma attaining sustained remission with bortezomib-combined dose-adjusted EPOCH therapy].
Kobayashi H; Miyagi N
Rinsho Ketsueki; 2017; 58(5):443-448. PubMed ID: 28592757
[TBL] [Abstract][Full Text] [Related]
12. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma.
Laubach JP; Tuchman SA; Rosenblatt JM; Mitsiades CS; Colson K; Masone K; Warren D; Redd RA; Grayson D; Richardson PG
Blood Cancer J; 2021 Feb; 11(2):20. PubMed ID: 33563894
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic hematopoietic stem cell transplantation in a patient with HIV-negative recurrent plasmablastic lymphoma: A case report.
Rong C; Sheng L; Wu A; Sun Y; Ouyang G
Medicine (Baltimore); 2021 Feb; 100(7):e24498. PubMed ID: 33607779
[TBL] [Abstract][Full Text] [Related]
15. Case of lymphadenopathy with lytic bone lesions.
Kalantri SA; Nath UK; Banerjee D; Bhattacharyya M
BMJ Case Rep; 2017 Mar; 2017():. PubMed ID: 28320703
[TBL] [Abstract][Full Text] [Related]
16. [Plasmablastic lymphoma].
Fernández-Álvarez R; Sancho JM; Ribera JM
Med Clin (Barc); 2016 Nov; 147(9):399-404. PubMed ID: 27576534
[TBL] [Abstract][Full Text] [Related]
17. Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham's Lymphangiomatosis: Review of the Literature.
Lee M; Martin BA; Abdulhaq H
Case Rep Hematol; 2022; 2022():8331766. PubMed ID: 35795542
[TBL] [Abstract][Full Text] [Related]
18. Plasmablastic lymphoma of the gastrointestinal tract: A rare entity with a dismal prognosis.
Komaranchath AS; Haleshappa RA; Kuntegowdenahalli LC; Kumar RV; Dasappa L; Babu G
Indian J Cancer; 2016; 53(4):529-533. PubMed ID: 28485344
[TBL] [Abstract][Full Text] [Related]
19. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma.
Akce M; Chang E; Haeri M; Perez M; Finch CJ; Udden MM; Mims MP
Case Rep Hematol; 2016; 2016():3598547. PubMed ID: 27957358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
